UNSPSC 51322003: Beloxamide

This classification denotes an anti-lipidemic agent with the molecular formula C18H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S4YR4X39CA, chemically known as acetamide, n-(phenylmethoxy)-n-(3-phenylpropyl)- but generally known as beloxamide, which bears US NIH Compound Identifier 27155. European Medicines Agency schedules Beloxamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05688MIG.

UNSPSC 51322003 Beloxamide is a Commodity code covering pharmaceutical ingredients and finished medications procured by state and local health agencies, fire rescue departments, and cooperative purchasing alliances to supply emergency medical services, institutional healthcare, and pharmacy benefit programs. State and local governments buy under this code primarily through municipal fire rescue services, state health and human services commissions, and multistate cooperative purchasing organizations that aggregate demand across multiple jurisdictions. The work solicited ranges from individual advanced life support medications for emergency response to bulk generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers to hospitals, clinics, and public health facilities across participating states.

Recent activity shows a geographic mix spanning Florida, Texas, and the upper Midwest, with the most visible procurement through multistate cooperative vehicles. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a response deadline of April 8, 2026; the solicitation included a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring vendors to supply through three authorized wholesalers with awards effective July 1, 2026 and a two-year term. The Texas Health and Human Services Commission issued an exploratory RFI in April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage state interest in direct pharmaceutical contracting outside traditional PBM and GPO channels.